The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells

Frontiers in Pharmacology

Volumn 5, Issue OCT, 2014, Pages

  Gargett, Tessa ^a   Brown, Michael P ^a,b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

AP1903; Cancer immunotherapy; Chimeric antigen receptor T cells; Inducible caspase9; Safety switch; Suicide gene

Indexed keywords

EID: 84908700977     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00235     Document Type: Article

References (75)

1. Annunziata, CM., Kohn, E.C., Lorusso, P., Houston, N.D., Coleman, R.L, Buzoianu, M., Robbie, G., and Lechleider, R. (2013). Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31, 77-84. doi: 10.1007/s10637-012-9801-2.
2. Berger, C, Flowers, M.E., Warren, E.H., and Riddell, S.R. (2006). Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294-2302. doi: 10.1182/blood-2005-08-3503.
3. Besser, M.J., Shapira-Frommer, R., Itzhaki, O., Treves, A.J., Zippel, D.B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y., Ohayon, D., Shalmon, B., Markel, G., Yerushalmi, R., Apter, S., Ben-Nun, A., Ben-Ami, E., Shimoni, A., Nagler, A., and Schachter, J. (2013). Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clin Cancer Res 19, 4792-4800. doi: 10.1158/1078-0432.CCR-13-0380.
4. Bonini, C, Bondanza, A., Perna, S.K., Kaneko, S., Traversari, C, Ciceri, F., and Bordignon, C. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15, 1248-1252. doi: 10.1038/sj.mt.6300190.
5. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., and Sadelain, M. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18, 666-668. doi: 10.1038/mt.2010.31.
6. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C, Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C, Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M., and Sadelain, M. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5, 177ra138. doi: 10.1126/scitranslmed.3005930.
7. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C, Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M., and Sadelain, M. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828. doi: 10.1182/blood-2011-04-348540.
8. Budde, L.E., Berger, C, Lin, Y., Wang, J., Lin, X., Frayo, S.E., Brouns, S.A., Spencer, D.M., Till, B.G., Jensen, M.C., Riddell, S.R., and Press, O.W. (2013). Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 8, e82742. doi: 10.1371/journal.pone.0082742.
9. Cattoglio, C, Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., Von Kalle, C, Howe, S., Thrasher, A.J., Aiuti, A., Ferrari, G., Recchia, A., and Mavilio, F. (2007). Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110, 1770-1778. doi: 10.1182/blood-2007-01-068759.
10. Chien, K.R. (2006). Herceptin and the heart--a molecular modifier of cardiac failure. N Engl J Med 354, 789-790. doi: 10.1056/NEJMp058315.
11. Ciceri, F., Bonini, C, Stanghellini, M.T., Bondanza, A., Traversari, C, Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S.K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Rossini, S., Santoro, A., Todisco, E., Apperley, J., Olavarria, E., Slavin, S., Weissinger, E.M., Ganser, A., Stadler, M., Yannaki, E., Fassas, A., Anagnostopoulos, A., Bregni, M., Stampino, C.G., Bruzzi, P., and Bordignon, C. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10, 489-500. doi: 10.1016/S1470-2045(09)70074-9.
12. Clackson, T., Yang, W., Rozamus, L.W., Hatada, M., Amara, J.F., Rollins, C.T., Stevenson, L.F., Magari, S.R., Wood, S.A., Courage, N.L, Lu, X., Cerasoli, F., Jr., Gilman, M., and Holt, D.A. (1998). Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95, 10437-10442.
13. Cooper, L.J., Ausubel, L, Gutierrez, M., Stephan, S., Shakeley, R., Olivares, S., Serrano, L.M., Burton, L., Jensen, M.C., Forman, S.J., and Digiusto, D.L. (2006). Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8, 105-117. doi: 10.1080/14653240600620176.
14. De Witte, M.A., Jorritsma, A., Swart, E., Straathof, K.C., De Punder, K., Haanen, J.B., Rooney, CM., and Schumacher, T.N. (2008). An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 180, 6365-6373.
15. Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C, Straathof, K., Liu, E., Durett, A.G., Grilley, B., Liu, H., Cruz, C.R., Savoldo, B., Gee, A.P., Schindler, J., Krance, R.A., Heslop, H.E., Spencer, D.M., Rooney, CM., and Brenner, M.K. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365, 1673-1683. doi: 10.1056/NEJMoa1106152.
16. Fridman, W.H., Pages, F., Sautes-Fridman, C, and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298-306. doi: 10.1038/nrc3245.
17. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C, Levine, B.L., and June, CH. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509-1518. doi: 10.1056/NEJMoa1215134.
18. Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C, Wang, G.P., Berry, C.C., Martinache, C, Rieux-Laucat, F., Latour, S., Belohradsky, B.H., Leiva, L., Sorensen, R., Debre, M., Casanova, J.L., Blanche, S., Durandy, A., Bushman, F.D., Fischer, A., and Cavazzana-Calvo, M. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363, 355-364. doi: 10.1056/NEJMoa1000164.
19. Hacein-Bey-Abina, S., Von Kalle, C, Schmidt, M., Le Deist, F., Wulffraat, N., Mcintyre, E., Radford, I., Villeval, J.L., Fraser, CC, Cavazzana-Calvo, M., and Fischer, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348, 255-256. doi: 10.1056/NEJM200301163480314.
20. Hamid, O., Robert, C, Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., Dronca, R., Gangadhar, T.C, Patnaik, A., Zarour, H., Joshua, A.M., Gergich, K., Elassaiss-Schaap, J., Algazi, A., Mateus, C, Boasberg, P., Tumeh, P.C, Chmielowski, B., Ebbinghaus, S.W., Li, X.N., Kang, S.P., and Ribas, A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369, 134-144. doi: 10.1056/NEJMoa1305133.
21. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, CM., Liu, H., Wu, M.F., Rochester, R.J., Amrolia, P.J., Hurwitz, J.L., Brenner, M.K., and Rooney, CM. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935. doi: 10.1182/blood-2009-08-239186.
22. Hodi, F.S., O'day, S.J., Mcdermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C, Schadendorf, D., Hassel, J.C, Akerley, W., Van Den Eertwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbe, C, Peschel, C, Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., and Urba, W.J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723. doi: 10.1056/NEJMoa1003466.
23. Hoyos, V., Savoldo, B., Quintarelli, C, Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, CM., Brenner, M.K., and Dotti, G. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160-1170. doi: 10.1038/leu.2010.75.
24. Iuliucci, J.D., Oliver, S.D., Morley, S., Ward, C, Ward, J., Dalgarno, D., Clackson, T., and Berger, H.J. (2001). Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41, 870-879.
25. Jensen, M.C., Popplewell, L., Cooper, L.J., Digiusto, D., Kalos, M., Ostberg, J.R., and Forman, S.J. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16, 1245-1256. doi: 10.1016/j.bbmt.2010.03.014.
26. Ji, J., Mould, D.R., Blum, K.A., Ruppert, A.S., Poi, M., Zhao, Y., Johnson, A.J., Byrd, J.C., Grever, M.R., and Phelps, M.A. (2013). A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 19, 1269-1280. doi: 10.1158/1078-0432.CCR-12-1092.
27. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L, Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., Lee, C.C., Restifo, N.P., Schwarz, S.L, Cogdill, A.P., Bishop, R.J., Kim, H., Brewer, C.C., Rudy, S.F., Vanwaes, C, Davis, J.L, Mathur, A., Ripley, R.T., Nathan, D.A., Laurencot, CM., and Rosenberg, S.A. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546. doi: 10.1182/blood-2009-03-211714.
28. Kalos, M., Levine, B.L, Porter, D.L, Katz, S., Grupp, S.A., Bagg, A., and June, C.H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3, 95ra73. doi: 10.1126/scitranslmed. 3002842.
29. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., Yang, J.C, Kammula, U.S., Devillier, L, Carpenter, R., Nathan, D.A., Morgan, R.A., Laurencot, C, and Rosenberg, S.A. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720. doi: 10.1182/blood-2011-10-384388.
30. Lamers, C.H., Sleijfer, S., Van Steenbergen, S., Van Elzakker, P., Van Krimpen, B., Groot, C, Vulto, A., Den Bakker, M., Oosterwijk, E., Debets, R., and Gratama, J.W. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21, 904-912. doi: 10.1038/mt.2013.17.
31. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., and Oosterwijk, E. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24, e20-22. doi: 10.1200/JCO.2006.05.9964.
32. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., Litzky, L., Bagg, A., Carreno, B.M., Cimino, P.J., Binder-Scholl, G.K., Smethurst, D.P., Gerry, A.B., Pumphrey, N.J., Bennett, A.D., Brewer, J.E., Dukes, J., Harper, J., Tayton-Martin, H.K., Jakobsen, B.K., Hassan, N.J., Kalos, M., and June, C.H. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871. doi: 10.1182/blood-2013-03-490565.
33. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C, Russell, H.V., Diouf, O., Liu, E., Liu, H., Wu, M.F., Gee, A.P., Mei, Z., Rooney, CM., Heslop, H.E., and Brenner, M.K. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056. doi: 10.1182/blood-2011-05-354449.
34. Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., and Pule, M. (2012). Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 23, 376-386. doi: 10.1089/hgtb.2012.050.
35. Maude, S.L, Barrett, D., Teachey, D.T., and Grupp, S.A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20, 119-122. doi: 10.1097/PPO.0000000000000035.
36. Maus, M.V., Grupp, S.A., Porter, D.L., and June, C.H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635. doi: 10.1182/blood-2013-11-492231.
37. Mocellin, S., Pasquali, S., Rossi, C.R., and Nitti, D. (2010). Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102, 493-501. doi: 10.1093/jnci/djq009.
38. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., Phan, G.Q., Hughes, M.S., Kammula, U.S., Miller, A.D., Hessman, C.J., Stewart, A.A., Restifo, N.P., Quezado, M.M., Alimchandani, M., Rosenberg, A.Z., Nath, A., Wang, T., Bielekova, B., Wuest, S.C., Akula, N., Mcmahon, F.J., Wilde, S., Mosetter, B., Schendel, D.J., Laurencot, CM., and Rosenberg, S.A. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36, 133-151. doi: 10.1097/CJI.0b013e3182829903.
39. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, CM., and Rosenberg, S.A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851. doi: 10.1038/mt.2010.24.
40. Murray, J.L, Cunningham, J.E., Brewer, H., Mujoo, K., Zukiwski, A.A., Podoloff, D.A., Kasi, L.P., Bhadkamkar, V., Fritsche, H.A., Benjamin, R.S., and et al. (1994). Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12, 184-193.
41. Newrzela, S., Al-Ghaili, N., Heinrich, T., Petkova, M., Hartmann, S., Rengstl, B., Kumar, A., Jack, H.M., Gerdes, S., Roeder, I., Hansmann, M.L, and Von Laer, D. (2012). T-cell receptor diversity prevents T-cell lymphoma development. Leukemia 26, 2499-2507. doi: 10.1038/leu.2012.142.
42. Newrzela, S., Cornils, K., Heinrich, T., Schlager, J., Yi, J.H., Lysenko, O., Kimpel, J., Fehse, B., and Von Laer, D. (2011). Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med 17, 1223-1232. doi: 10.2119/molmed.2010.00193.
43. Newrzela, S., Cornils, K., Li, Z., Baum, C, Brugman, M.H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.L., Fehse, B., and Von Laer, D. (2008). Resistance of mature T cells to oncogene transformation. Blood 112, 2278-2286. doi: 10.1182/blood-2007-12-128751.
44. Park, J.H., and Brentjens, R.J. (2010). Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 9, 277-288.
45. Parkhurst, M.R., Yang, J.C, Langan, R.C, Dudley, M.E., Nathan, D.A., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M., Hughes, M.S., Kammula, U.S., Phan, G.Q., Lim, R.M., Wank, S.A., Restifo, N.P., Robbins, P.F., Laurencot, CM., and Rosenberg, S.A. (2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19, 620-626. doi: 10.1038/mt.2010.272.
46. Perez-Soler, R., Delord, J.P., Halpern, A., Kelly, K., Krueger, J., Sureda, B.M., Von Pawel, J., Temel, J., Siena, S., Soulieres, D., Saltz, L., and Leyden, J. (2005). HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10, 345-356. doi: 10.1634/theoncologist.10-5-345.
47. Porter, D.L, Levine, B.L, Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725-733. doi: 10.1056/NEJMoa1103849.
48. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C, Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., Yvon, E., Weiss, H.L., Liu, H., Rooney, CM., Heslop, H.E., and Brenner, M.K. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14, 1264-1270. doi: 10.1038/nm.1882.
49. Pule, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, CM., and Brenner, M.K. (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12, 933-941. doi: 10.1016/j.ymthe. 2005.04.016.
50. Quintarelli, C, Vera, J.F., Savoldo, B., Giordano Attianese, G.M., Pule, M., Foster, A.E., Heslop, H.E., Rooney, CM., Brenner, M.K., and Dotti, G. (2007). Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110, 2793-2802. doi: 10.1182/blood-2007-02-072843.
51. Recchia, A., Bonini, C, Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico, E., Bondanza, A., Stanghellini, M.T., Bernardi, M., Pescarollo, A., Ciceri, F., Bordignon, C, and Mavilio, F. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103, 1457-1462. doi: 10.1073/pnas.0507496103.
52. Restifo, N.P., Dudley, M.E., and Rosenberg, S.A. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12, 269-281. doi: 10.1038/nri3191.
53. Riddell, S.R., Elliott, M., Lewinsohn, D.A., Gilbert, M.J., Wilson, L., Manley, S.A., Lupton, S.D., Overell, R.W., Reynolds, T.C, Corey, L., and Greenberg, P.D. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2, 216-223.
54. Rosenberg, S.A. (2014). IL-2: the first effective immunotherapy for human cancer. J Immunol 192, 5451-5458. doi: 10.4049/jimmunol. 1490019.
55. Rosenberg, S.A., and Dudley, M.E. (2004). Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101 Suppl 2, 14639-14645. doi: 10.1073/pnas.0405730101.
56. Saleh, M.N., Khazaeli, M.B., Wheeler, R.H., Dropcho, E., Liu, T., Urist, M., Miller, D.M., Lawson, S., Dixon, P., Russell, C.H., and et al. (1992). Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52, 4342-4347.
57. Sangiolo, D., Leuci, V., Gallo, S., Aglietta, M., and Piacibello, W. (2011). Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. Expert Opin Biol Ther 11, 655-666. doi: 10.1517/14712598.2011.565325.
58. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, CM., Gee, A.P., Mei, Z., Liu, H., Grilley, B., Rooney, CM., Heslop, H.E., Brenner, M.K., and Dotti, G. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121, 1822-1826. doi: 10.1172/JCI46110.
59. Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, A.N., Kalos, M., Riley, J.L., Deeks, S.G., Mitsuyasu, R.T., Bernstein, W.B., Aronson, N.E., Levine, B.L., Bushman, F.D., and June, C.H. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4, 132ra153. doi: 10.1126/scitranslmed.3003761.
60. Seliger, B. (2008). Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57, 1719-1726. doi: 10.1007/s00262-008-0515-4.
61. Seliger, B., Harders, C, Wollscheid, U., Staege, M.S., Reske-Kunz, A.B., and Huber, C. (1996). Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 24, 1275-1279.
62. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111. doi: 10.1038/35074122.
63. Sorkin, L.S., Otto, M., Baldwin, W.M., 3rd, Vail, E., Gillies, S.D., Handgretinger, R., Barfield, R.C., Ming Yu, H., and Yu, A.L (2010). Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149, 135-142. doi: 10.1016/j.pain.2010.01.024.
64. Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop, H.E., Spencer, D.M., and Rooney, CM. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247-4254. doi: 10.1182/blood-2004-11-4564.
65. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., and Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355, 1018-1028. doi: 10.1056/NEJMoa063842.
66. Teachey, D.T., Rheingold, S.R., Maude, S.L, Zugmaier, G., Barrett, D.M., Seif, A.E., Nichols, K.E., Suppa, E.K., Kalos, M., Berg, R.A., Fitzgerald, J.C., Aplenc, R., Gore, L., and Grupp, S.A. (2013). Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154-5157. doi: 10.1182/blood-2013-02-485623.
67. Tey, S.K., Dotti, G., Rooney, CM., Heslop, H.E., and Brenner, M.K. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13, 913-924. doi: 10.1016/j.bbmt. 2007.04.005.
68. Topalian, S.L., Sznol, M., Mcdermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., Lawrence, D.P., Atkins, M.B., Powderly, J.D., Leming, P.D., Lipson, E.J., Puzanov, I., Smith, D.C, Taube, J.M., Wigginton, J.M., Kollia, G.D., Gupta, A., Pardoll, D.M., Sosman, J.A., and Hodi, F.S. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32, 1020-1030. doi: 10.1200/JCO.2013.53.0105.
69. Wang, X., Naranjo, A., Brown, C.E., Bautista, C, Wong, C.W., Chang, W.C, Aguilar, B., Ostberg, J.R., Riddell, S.R., Forman, S.J., and Jensen, M.C. (2012). Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 35, 689-701. doi: 10.1097/CJI.0b013e318270dec7.
70. Willmon, C.L, Krabbenhoft, E., and Black, M.E. (2006). A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther 13, 1309-1312. doi: 10.1038/sj.gt.3302794.
71. Wolchok, J.D., Weber, J.S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L, De Pril, V., Humphrey, R., and Lebbe, C. (2013). Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 24, 2174-2180. doi: 10.1093/annonc/mdt161.
72. Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751. doi: 10.1126/science. 1083413.
73. Yang, H., Rosove, M.H., and Figlin, R.A. (1999). Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 62, 247-250.
74. Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., Shimada, H., Grupp, S.A., Seeger, R., Reynolds, C.P., Buxton, A., Reisfeld, R.A., Gillies, S.D., Cohn, S.L., Maris, J.M., Sondel, P.M., and Children's Oncology, G. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363, 1324-1334. doi: 10.1056/NEJMoa0911123.
75. Zhou, X., Di Stasi, A., Tey, S.K., Krance, R.A., Martinez, C, Leung, K.S., Durett, A.G., Wu, M.F., Liu, H., Leen, A.M., Savoldo, B., Lin, Y.F., Grilley, B.J., Gee, A.P., Spencer, D.M., Rooney, CM., Heslop, H.E., Brenner, M.K., and Dotti, G. (2014). Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123, 3895-3905. doi: 10.1182/blood-2014-01-551671.